Beeline Medicines’ Phase II SLE trial of afimetoran meets primary endpoint

Afimetoran Phase II SLE Trial Achieves Primary Endpoint

Beeline Medicines announced positive top-line results from its global Phase II clinical trial evaluating afimetoran in 248 adults with active moderate-to-severe systemic lupus erythematosus (SLE). The trial met its primary endpoint, demonstrating significantly higher SLE Responder Index-4 (SRI-4) response rates at week 48 across all three once-daily oral afimetoran dose groups compared to placebo (p<0.001). The drug was generally well tolerated, with a safety profile consistent with previous studies, and no new safety signals were observed. This outcome supports afimetoran's potential as a foundational oral therapy for lupus patients, with plans to advance into pivotal development.

• Significant Efficacy Demonstrated: The Phase II trial successfully achieved its primary endpoint, showing that all three doses of once-daily oral afimetoran led to statistically significant improvements in SLE Responder Index-4 (SRI-4) response rates at week 48 compared to placebo, with a p-value of less than 0.001 across all dose groups. This indicates a robust therapeutic effect in patients with moderate-to-severe SLE.
• Favorable Safety and Tolerability Profile: Afimetoran was generally well tolerated throughout the trial, with its safety profile aligning with findings from a previous Phase I study. Importantly, no new safety signals emerged during the trial period, reinforcing confidence in the drug's safety for long-term use in the target patient population.
• Strategic Development and Regulatory Recognition: Afimetoran, originally discovered by Bristol Myers Squibb and licensed to Beeline Medicines in July 2025, has already received Fast Track designation from the US FDA for SLE in May 2025. These positive Phase II results strengthen the company's conviction to advance afimetoran into pivotal development, aiming to address the urgent need for new oral treatment options for lupus patients.

Afimetoran's Positive Phase II Results in Moderate-to-Severe SLE

Several recent clinical trials and systematic analyses have examined the efficacy and safety of biological and targeted therapies in SLE. The TULIP-1 and TULIP-2 phase 3 trials, along with the phase 2b MUSE trial, evaluated anifrolumab (300 mg intravenously every 4 weeks). Across these trials, most patients (78%–85%) had concordant BILAG-based Composite Lupus Assessment (BICLA) and SLE Responder Index (SRI(4)) outcomes, with dual BICLA/SRI(4) response rates favouring anifrolumab over placebo in all three trials (all nominal p≤0.004). A long-term extension, the TULIP-LTE trial, further assessed anifrolumab 300 mg in Japanese patients over three years; exposure-adjusted incidence rates of serious adverse events (SAEs) during the long-term extension period were 8.7 per 100 patient-years, with adverse events of special interest including influenza (6.9 per 100 patient-years) and herpes zoster (3.5 per 100 patient-years). Sustained reductions from baseline in mean SLEDAI-2K scores and cumulative glucocorticoid dosage were observed during the combined TULIP+LTE period. A broader systematic review and network meta-analysis (PROSPERO registration CRD42024594766), encompassing 32 studies and 17,121 patients, found that anifrolumab demonstrated advantages in Cutaneous Lupus Erythematosus Disease Area and Severity Index-50 (CLASI-50) improvement, though it was associated with a higher incidence of adverse events including upper respiratory tract infections, urinary tract infections, and herpes zoster.

The BLISS-LN trial evaluated belimumab, an inhibitor of B-cell activating factor, as an add-on therapy to steroids and either mycophenolate mofetil (MMF) or cyclophosphamide, administered intravenously monthly over 104 weeks, demonstrating an effect size of 11% for a Primary Efficacy Renal Response. In a real-world multicentre observational study of 122 patients with active lupus nephritis receiving intravenous belimumab, the proportions achieving complete renal response (CRR), partial renal response (PRR), no renal response (NRR), and primary efficacy renal response (PERR) were 35.9%, 17.1%, 47.0%, and 44.4% at 6 months, improving to 55.6%, 19.4%, 26.4%, and 58.3% at 12 months, respectively. Baseline anti-dsDNA positivity inversely predicted NRR at 6 months (OR=0.32, 95% CI=0.10 to 0.98, p=0.049), while anti-SSA/Ro60 positively predicted NRR at 6 months (OR=3.16, 95% CI=1.14 to 8.74, p=0.027). The AURORA trial assessed voclosporin, a calcineurin inhibitor, as an oral add-on to low-dose steroids and MMF given twice daily over 52 weeks, reporting an effect size of 18.5% for CRR. In the real-world VoRLiSS study (42 patients, 14 Italian centres), 31.5% of patients achieved CRR or PRR at 6 weeks, rising to 68.9% at 12 weeks, 83.3% at 24 weeks, and 91.6% at 48 weeks, with a significant decrease in 24-hour proteinuria observed as early as 6 weeks (p=0.006).

An integrated safety analysis of evobrutinib, a Bruton's tyrosine kinase inhibitor, pooled phase II data from 1,083 patients across multiple sclerosis, rheumatoid arthritis, and SLE trials (SLE: n=480, 52 weeks). Across indications, the proportion of patients with treatment-emergent adverse events (TEAEs) and the exposure-adjusted incidence rate (EAIR) were similar for evobrutinib and placebo (66.2% [247.6 events/100 patient-years] vs 62.4% [261.4 events/100 patient-years]). In the SLE cohort specifically, the EAIR of TEAEs was 343.0 versus 302.1 events/100 patient-years for evobrutinib versus placebo. The serious infections EAIR was 2.7 and 2.1 events/100 patient-years for evobrutinib and placebo, respectively. A comprehensive systematic review of infectious complications across SLE clinical trials further highlighted that herpes zoster was strongly associated with active lupus nephritis and anifrolumab therapy (OR 2.8, 95% CI 1.18 to 6.66, p=0.018), and that serious adverse events and infectious complications occurred more frequently in placebo-treated patients with active lupus nephritis, particularly in the BLISS-LN and LUNAR (rituximab) trials.

Unpacking the Phase II Design and Afimetoran's TLR7/8 Inhibition

Several key randomised controlled trials in SLE have employed rigorous double-blind, placebo-controlled designs across phase 1 through phase 3 settings, evaluating a range of pharmacological mechanisms and composite disease activity endpoints. The trials span oral small molecules, biologics, and cytokine-based therapies, with primary endpoints anchored to validated SLE-specific responder indices assessed at 24 to 52 weeks.

Addressing Persistent Unmet Needs in Moderate-to-Severe SLE

Current SLE management is complicated by the disease's clinical heterogeneity, the toxicity burden of long-standing therapies, and an incomplete evidence base for newer biological agents. Identifying which patients will benefit most from specific treatment protocols remains a central unresolved challenge for both clinicians and drug developers.

• Glucocorticoid-related harm: Glucocorticoids (GCs) remain a cornerstone of SLE therapy, yet their long-term dosage-related collateral effects have driven the search for steroid-sparing alternatives. Treatment strategies now emphasize methylprednisolone pulses for moderate-to-severe flares followed by low-to-moderate doses of oral prednisone with quick tapering to maintenance doses of ≤5 mg/day, reflecting the recognized need to minimize cumulative GC exposure.

• Heterogeneity in steroid-sparing evidence: A scoping review of phase II and phase III randomized, placebo-controlled trials found that, of eight RCTs evaluating biological agents (7 belimumab; 1 anifrolumab), only four demonstrated a definite steroid-sparing effect. A degree of heterogeneity in steroid regimen protocols — including initial dosage, tapering schedules, and rescue treatment allowance — was observed across studies, leaving the evidence on the steroid-sparing effect of biologics "scattered."

• Refractory and severe disease: Severe or refractory SLE can cause irreversible organ damage and contribute to disease morbidity and mortality. Evidence from well-designed randomized controlled trials in this population is limited, and early recognition of life-threatening conditions involving neuropsychiatric, gastrointestinal, hematologic, renal, pulmonary, and cardiovascular systems poses significant clinical challenges.

• Neuropsychiatric SLE (NPSLE): NPSLE poses significant challenges due to its clinical diversity and obscure pathophysiology. The role of biologics other than rituximab in refractory NPSLE remains unknown, and advances in biomarkers and neuroimaging for brain structural, perfusion, or functional abnormalities are still needed to optimize management.

• Pharmacogenomic safety risks with immunosuppressants: Azathioprine (AZA), a commonly used immunosuppressant in SLE, carries the risk of severe myelosuppression linked to variations in thiopurine S-methyltransferase (TPMT) enzyme activity. A case of AZA-induced fatal myelosuppression associated with the TPMT*3C heterozygous mutant allele — presenting with pancytopenia, sepsis, typhlitis, and disseminated intravascular coagulopathy — illustrates that genetic risk stratification remains an underutilized safeguard in routine practice.

• Patient stratification for targeted biologics: Future research needs to pursue the identification of precise SLE clusters of patients who would benefit most from a specific treatment protocol with a definite steroid-sparing effect, underscoring that current biological approvals have not yet resolved the question of optimal patient selection.

Afimetoran's Positive Phase II: A Pivotal Step in Oral SLE Therapy

The recent announcement of positive Phase II results for afimetoran in moderate-to-severe systemic lupus erythematosus (SLE) represents a significant moment for patients and the pharmaceutical industry. For individuals living with SLE, a chronic and debilitating autoimmune disease, the prospect of a new, effective, and conveniently administered oral therapy is highly encouraging. Afimetoran's success in meeting its primary endpoint, the SLE Responder Index-4 (SRI-4) response, at week 48, indicates a meaningful improvement in systemic disease activity, a critical measure in clinical trials for this complex condition.

This development is particularly noteworthy given the drug's profile: an oral, once-daily formulation. This offers a substantial advantage in patient convenience and adherence compared to intravenous biologics, which currently dominate parts of the SLE treatment landscape. Furthermore, afimetoran is identified as a Toll-like Receptor (TLR) 7/8 antagonist, suggesting a distinct mechanism of action that could offer a valuable alternative for patients who may not respond adequately to existing therapies.

However, the journey from Phase II success to market approval is not without its challenges. While the drug was generally well tolerated with no new safety signals observed in this trial, the long-term safety profile of any immunomodulatory therapy is paramount. Studies indicate that other agents in this class can be associated with increased risks of infections, such as herpes zoster or respiratory infections, over extended periods. Therefore, rigorous monitoring in larger, pivotal Phase III trials will be crucial to fully characterize afimetoran's long-term safety and tolerability. Its ultimate success will also hinge on its ability to differentiate itself in a competitive market, not only through its oral convenience but also by demonstrating sustained efficacy and a favorable safety profile against a growing array of biologics and targeted small molecules. If these hurdles are successfully navigated, afimetoran could indeed emerge as a foundational oral therapy, offering a new beacon of hope for SLE patients.